What we disagree on is immaterial to NAN's outlook.
It is now approaching 3 weeks since Q3 FY 2024.
If NAN failed in their targeting of Coris readiness for FDA submission by the end of Q3 then Mr Kavanagh would be obliged to let the ASX know.
There was no such ASX announcement. I conclude NAN met its target.
No obligation to announce a formal submission
NAN Chart, page-164
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.85 |
Change
0.030(1.06%) |
Mkt cap ! $863.4M | |||
| Open | High | Low | Value | Volume |
| $2.81 | $2.87 | $2.81 | $1.167M | 409.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 45303 | $2.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.86 | 4094 | 2 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.86 |
Change
0.030 ( 0.94 %) |
||||
| Open | High | Low | Volume | ||
| $2.81 | $2.87 | $2.81 | 124972 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| NAN (ASX) Chart |